The second generation mTOR inhibitor OSI-027 is used in phase I gastric cancer, causing a decrease in proliferation and antiangiogenetic capacities, and antitumor activity in several cancers such as the prostate, renal, and bladder (Tian et al. 2019). Here, MTOR is linked to cancer.